

## ONCOLOGY AGENTS, BREAST CANCER PRIOR AUTHORIZATION FORM

- Please complete all applicable sections of this prior authorization request form and return to the fax number above. Please **include all requested documentation** (chart notes, laboratory data, etc.).
- To review the prior authorization guidelines for Breast Cancer Oncology Agents, please refer to the Medical Assistance Prior Authorization of Pharmaceutical Services Handbook Chapter – **Oncology Agents, Breast Cancer** (accessible at: <http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization/index.htm>).
- These agents are also subject to quantity limits. If the requested quantity exceeds the limit, please submit supporting chart documentation (refer to Quantity Limits list at: <http://www.dhs.pa.gov/provider/pharmacyservices/quantitylimitslist/index.htm>).

PRIOR AUTHORIZATION REQUEST INFORMATION			PRESCRIBER INFORMATION		
<input type="checkbox"/> New request	<input type="checkbox"/> Additional info	# of pages in request: _____	Prescriber name:		
<input type="checkbox"/> Renewal request	PA#: _____	request: _____			
Name of office contact:			Specialty:		
Contact's phone number:			State license #:		
Facility contact/phone:			NPI:	MA Provider ID#:	
RECIPIENT INFORMATION			Street address:		
Recipient Name:			Suite #:	City/state/zip:	
Recipient ID#:	DOB:	Phone:	Fax:		

## CLINICAL INFORMATION

<b>Non-preferred medication requested:</b>				<input type="checkbox"/> Arimidex tablet	<input type="checkbox"/> Fareston tablet	<input type="checkbox"/> Soltamox solution
				<input type="checkbox"/> Aromasin tablet	<input type="checkbox"/> Femara tablet	
Strength:	Directions:	Quantity:	Refills:			
1. What is the Recipient's diagnosis?					<i>Submit documentation confirming diagnosis, such as chart notes, lab results, biopsy results, etc.</i>	
2. What is the corresponding diagnosis code?						
<b>For Fareston and Soltamox requests, go to question 3. For all other non-preferred requests, go to question 4.</b>						
3. <b><i>For Fareston and Soltamox requests only</i></b> , does the Recipient have a history of trial and failure, contraindication, or intolerance of the preferred alternative agent, <b>tamoxifen tablet</b> ?					<input type="checkbox"/> Yes – <i>submit all supporting documentation of tamoxifen regimen tried and treatment outcomes</i> <input type="checkbox"/> No	
4. <b><i>For all other requests</i></b> , does the Recipient have a history of trial and failure, contraindication, or intolerance of the preferred Breast Cancer Oncology Agents? <i>Check all that apply.</i>					<input type="checkbox"/> Yes – <i>submit all supporting documentation of preferred drug regimen tried and treatment outcomes</i> <input type="checkbox"/> No	
<input type="checkbox"/> anastrozole tablet <input type="checkbox"/> letrozole tablet <input type="checkbox"/> exemestane tablet						

**PLEASE FAX COMPLETED FORM WITH SUPPORTING CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

<b>Prescriber Signature:</b>	<b>Date:</b>
------------------------------	--------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.